Login Register
icon_bulk_orderBulk order Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
GMP IL-15 NEW |Streptavidin（SA） Hot |Claudin 18.2 |CD3 |GPCRs
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > DDC

DDC

Brief Information

Name:Aromatic-L-amino-acid decarboxylase
Target Synonym:EC:4.1.1.28,EC 4.1.1,DDC,AADC,Dopa Decarboxylase (Aromatic L-Amino Acid Decarboxylase),Aromatic-L-Amino-Acid Decarboxylase,Aromatic L-Amino Acid Decarboxylase,EC 4.1.1.28,DOPA decarboxylase
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
DDC-H55H6 Human Human DDC / Dopa Decarboxilase Protein, His Tag
DDC-H55H6-structure
ACRO Quality

Synonym Name

Aromatic-L-amino-acid decarboxylase,Dopa decarboxilase

Background

Dopa decarboxilase (DDC), also known as aromatic amino acid decarboxylase, is a group II decarboxylase. The enzyme catalyzes the decarboxylation of aromatic L-amino acids to produce the corresponding amines. DDC produces the neurotransmitters dopamine and serotonin from L-Dopa and L-5-hydroxytryptophan, respectively.  DDC inhibitors is in clinical use to treat Parkinson's disease(PD), usually co-administrated with L-DOPA. DDC would block peripheral conversion to dopamine and allow a greater percentage of L-DOPA to reach the brain, causing an increase in brain dopamine levels, and reducing the side effects of dopamine-rich blood.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Benserazide Hydrochloride Approved Mainland China Parkinson Disease; Dyskinesias Shanghai Yishengyuan Pharmaceutical Co Ltd 1995-01-01 Dyskinesias; Parkinson Disease Details
Carbidopa MK-486 Approved Lodosyn Mainland China Parkinson Disease Nantong Jinghua Pharmaceutical Co Ltd 1977-04-25 Postural Orthostatic Tachycardia Syndrome; Parkinson Disease; Orthostatic Intolerance Details
Carbidopa/Entacapone/Levodopa ODM-101; ELC-200 Approved Orion Pharma Trigel, LECIGel, 达灵复, Stalevo, LECIGon Japan Parkinson Disease Novartis Pharma Ag 2003-06-11 Parkinson Disease Details
Levodopa/Carbidopa IPX-054; AP-09004; DM-1992; AP-CDLD; TPI-926; IPX-066; ABT-SLV-187; AP-CD/LD; ND-0612; ND-0680; ND-0612L; ND-0612H; PW-4153; LCIG; ABT-SLV187; IPX-203; CP-012; JM-012; SOL-707; INP-107(POD™ carbidopa/levodopa) Approved Merck Sharp & Dohme Corp Nacom (imciromab), Nacom retard, Parcopa, Patrome, DopaFuse, Sinemet, Numient, Menesit, Duodopa, Vadova, Rytary, Isicom, Duopa Mainland China Parkinson Disease Jinghua Pharmaceutical Group Co Ltd 1975-05-02 Amblyopia; Amyotrophic Lateral Sclerosis; Diabetic Retinopathy; Diabetes Mellitus; Albinism; Cocaine-Related Disorders; Cognitive Dysfunction; Depressive Disorder, Treatment-Resistant; Albinism, Oculocutaneous; Gait Apraxia; Parkinson Disease; Aphasia, Broca; Stroke; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Depression; Motor Neuron Disease Details
Eladocagene exuparvovec PTC-AADC Approved National Taiwan University, Ptc Therapeutics Inc Upstaza United Kingdom Aromatic amino acid decarboxylase deficiency Ptc Therapeutics Inc 2022-07-18 Aromatic amino acid decarboxylase deficiency; Amino Acid Metabolism, Inborn Errors Details
Carbidopa/Melevodopa V-1512; GT-1512; CHF-1512; CNP-1512 Approved Chiesi Farmaceutici SPA Sirio Italy Parkinson Disease null 2003-01-01 Parkinson Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Buspirone/Carbidopa/Levodopa Phase 2 Clinical Universite Laval Spinal Cord Injuries; Multiple Sclerosis Details
Levodopa/Carbidopa controlled release tablets-night(WD Pharmaceutical) WD-1905 Phase 2 Clinical Parkinsonian Disorders Details
Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) WD-1603 Phase 2 Clinical Parkinsonian Disorders Details
Levodopa/Carbidopa(WD Pharmaceutical) WD-1804 Phase 1 Clinical Parkinsonian Disorders Details
Levodopa/Carbidopa granule(WD Pharmaceutical) WD-2010 Phase 1 Clinical Parkinsonian Disorders Details
Ezaladcigene resoparvovec GZ-404477; AV-201; VY-AADC02; VY-AADC; VY-AADC01 Phase 1 Clinical University Of California, Voyager Therapeutics Inc Aromatic amino acid decarboxylase deficiency; Parkinson Disease Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap